Cart
×
BACK TO SCHOOL: Communicating with the Team
Guest blog by Celeste Graham, PT, ex-Director of Physical Therapy, CureDuchenne CaresUPDATED 8/12/2022 We are at that time of year when the shelves of our local superstores that just recently […]
Navigating College, Living with Duchenne
Guest blog by Hawken Miller For those with Duchenne Muscular Dystrophy the experience and education of a four-year university is likely within your grasp, and being away from home […]
Tivorsan Pharmaceuticals Granted FDA Orphan Drug Designation for Human Recombinant Biglycan in the Treatment of Duchenne Muscular Dystrophy
FDA Accepts Marathon Pharmaceuticals’ New Drug Applications for Deflazacort for the Treatment of Duchenne Muscular Dystrophy and Grants Priority Review
PhaseBio Announces Dosing of First Patients in Two-Part Phase 2a Study of PB1046 in Cardiopulmonary Disorders
Pfizer, Bamboo and CureDuchenne – An Endorsement on the Right Track
Today, we are very pleased to announce that Pfizer has acquired Bamboo Therapeutics, a gene therapy company we invested in earlier this year through CureDuchenne Ventures. The deal is valued […]
Bamboo Therapeutics
Approach: Gene therapy for Duchenne
Funding Impact: Accelerated vector manufacturing capabilities
Successful Exit: Acquired by Pfizer in August 2016
Bamboo Therapeutics Acquired by Pfizer Inc., Early Stage Investment by CureDuchenne Ventures, LLC Enabled Bamboo Therapeutics to Accelerate Development of a Gene Therapy for Duchenne Muscular Dystrophy
NEWPORT BEACH, Calif., Aug. 1, 2016 – Today, Pfizer Inc. announced its acquisition of Bamboo Therapeutics in a deal worth up to $645 million. Bamboo Therapeutics is an early-stage biotechnology […]